54-week results on infliximab attract attention at EULAR. European League against Rheumatism.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/DBFACAB8.svg?ark=w1%2F20260515%2FDBFACAB8)](https://nobleid.org/work/w1/20260515/DBFACAB8)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors